Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 5, 2013, Pages

  Ronellenfitsch, Ulrich ^a   Schwarzbach, Matthias ^b   Hofheinz, Ralf ^a   Kienle, Peter ^a   Kieser, Meinhard ^c   Slanger, Tracy E ^d   Jensen, Katrin ^c   Burmeister, Bryan ^e   Kelsen, David ^f   Niedzwiecki, Donna ^g   Schuhmacher, Christoph ^h   Urba, Susan ⁱ   van de Velde, Cornelis ^j   Walsh, Thomas N ^k   Ychou, Marc ^l  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SANOFI   (France)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d INSTITUTE FOR QUALITY AND EFFICIENCY IN HEALTH CARE IQWIG   (Germany)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^j LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^k Royal College of Surgeons in Ireland   (Ireland)

^l Anticancer Center   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DOCETAXEL; DOXIFLURIDINE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; MITOMYCIN; PLATINUM; VINBLASTINE; ANTINEOPLASTIC AGENT;

AGE DISTRIBUTION; CANCER LOCALIZATION; CANCER MORTALITY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS RESECTION; GASTRECTOMY; GASTROESOPHAGEAL JUNCTION; HAZARD RATIO; HUMAN; INTENTION TO TREAT ANALYSIS; MORBIDITY; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POPULATION RESEARCH; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REVIEW; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURGICAL MORTALITY; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ADENOCARCINOMA; ESOPHAGUS TUMOR; LOWER ESOPHAGUS SPHINCTER; META ANALYSIS; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SQUAMOUS CELL CARCINOMA; STOMACH TUMOR; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; PROCEDURES; STOMACH NEOPLASMS; SURGERY;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS;

EID: 84891679783     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008107.pub2     Document Type: Review

References (76)

1. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology 2011;29(13):1715-21.
2. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al.Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of Clinical Oncology 2008;26(7):1086-92.
3. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al.Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology 2010;28(35):5210-8.
4. Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, et al.Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. European Journal of Surgical Oncology 2004;30(6):643-9.
5. Feng L-M, Li G, Sun X-C, Zhu S-G. Treatment out come of neoadjuvant chemotherapy for Bormann's type IV gastric cancer. Chinese Journal of Cancer Prevention and Treatment 2008;15(13):1022-4.
6. Kobayashi T. Long-term outcome of preoperative chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR) for gastric cancer. Gan to Kagaku Ryoho 2000;27(10):1521-6.
7. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine 2006;355(1):11-20.
8. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. Journal of Clinical Oncology 2009;27(30):5062-7.
9. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, et al.Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology 2007;25(24):3719-25.
10. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, et al.Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncology 2005;6(9):659-68.
11. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. Journal of Clinical Oncology 2001;19(2):305-13.
12. Walsh TN, Grennell M, Mansoor S, Kelly A. Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Diseases of the Esophagus 2002;15(2):121-4.
13. Wang XL, Wu GX, Zhang MD, Guo M, Zhang H, Sun XF. A favorable impact of preoperative FPLC chemotherapy on patients with gastric cardia cancer. Oncology Reports 2000;7(2):241-4.
14. Zhao WH, Wang SF, Ding W, Sheng JM, Ma ZM, Teng LS, et al.Apoptosis induced by preoperative oral 5'-DFUR administration in gastric adenocarcinoma and its mechanism of action. World Journal of Gastroenterology 2006;12(9):1356-61.
15. Bokhyan V, Stilidi I, Malikhova O, Tryakin A. Neoadjuvant chemotherapy followed by transthoracic resection for locally advanced carcinoma of the esophagus: A randomized study. European Journal of Cancer, Supplement. Elsevier Ltd, 2009; Vol. 7, issue 2-3:377.
16. Furlong H, Gilani N, Atie M, Bass G, Mulligan E, Keeling N, et al.Is the short-term survival advantage for neoadjuvant chemoradiotherapy in oesophageal cancer sustained? Long-term follow-up of two randomised trials. Diseases of the Esophagus. Blackwell Publishing, 2010; Vol. 23:74A.
17. Jin M-G, Jiang S-C, Chen Z-W, Wang Z-Q. Clinical trial of preoperative concurrent chemoradiation followed by surgery versus surgery alone for advanced esophageal carcinoma. Chinese Journal of Cancer Prevention and Treatment 2008;15(23):1815-7.
18. Jin FL, Hu ZL, Ma HF. Treatment effect of neoadjuvant chemoradiotherapy followed by surgery versus surgery alone in local advanced esophageal carcinoma. Journal of Practical Oncology. Journal of Practical Oncology, Editorial Board (31009China), 2011; Vol. 26, issue 5:523-6.
19. Mariette C, Seitz JF, Maillard E, Mornex F, Thomas PA, Raoul J, et al.Surgery alone versus chemoradiotherapy followed by surgery for localized esophageal cancer: Analysis of a randomized controlled phase III trial FFCD 9901. ASCO Meeting Abstracts 2010;28(15 Suppl):4005.
20. Pokataev I, Tryakin A, Stilidi I, Kononets P, Polotskiy B, Malikhova O, et al.Preoperative chemotherapy followed by surgery versus surgery alone in resectable esophageal cancer: A single institute phase III TRIAL. Annals of Oncology. Oxford University Press, 2008; Vol. 19, issue S8:viii170.
21. van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, Henegouwen MI, Wijnhoven BPL, et al.Preoperative chemoradiotherapy for esophageal or junctional cancer. New England Journal of Medicine 2012;366(22):2074-84.
22. Ajani JA, Mayer RJ, Ota DM, Steele GD, Evans D, Roh M, et al.Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. Journal of the National Cancer Institute 1993;85(22):1839-44.
23. Ajani JA, Mansfield PF, Ota DM. Potentially resectable gastric carcinoma: current approaches to staging and preoperative therapy. World Journal of Surgery 1995;19(2):216-20.
24. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, et al.Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. Journal of Clinical Oncology 2004;22(14):2774-80.
25. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, et al.Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. Journal of Clinical Oncology 2005;23(6):1237-44.
26. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, et al.Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. Journal of Clinical Oncology 2006;24(24):3953-8.
27. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088-101.
28. Biffi R, Fazio N, Luca F, Chiappa A, Andreoni B, Zampino MG, et al.Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World Journal of Gastroenterology 2010;16(7):868-74. [PUBMED: 20143466].
29. Burmeister BH, Thomas JM, Burmeister EA, Walpole ET, Harvey JA, Thomson DB, et al.Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial. European Journal of Cancer 2011;47(3):354-60.
30. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data. Journal of Clinical Oncology 2004;22(12):2395-403. [PUBMED: 15197201].
31. Chau I, Norman AR, Cunningham D, Oates J, Hawkins R, Iveson T, et al.The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials. Annals of Oncology 2009;20(5):885-91.
32. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Annals of Surgical Oncology 2006;13(1):12-30.
33. Dikken JL, van Sandick JW, Maurits Swellengrebel HA, Lind PA, Putter H, Jansen EP, et al.Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer 2011;11:329. [PUBMED: 21810227].
34. Djarv T, Metcalfe C, Avery KN, Lagergren P, Blazeby JM. Prognostic value of changes in health-related quality of life scores during curative treatment for esophagogastric cancer. Journal of Clinical Oncology 2010;28(10):1666-70. [PUBMED: 20194863].
35. Djarv T, Lagergren P. Quality of life after esophagectomy for cancer. Expert Review of Gastroenterology and Hepatology 2012;6(1):115-22. [PUBMED: 22149587].
36. Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-34.
37. Eguchi T, Kodera Y, Nakanishi H, Yokoyama H, Ohashi N, Ito Y, et al.The effect of chemotherapy against micrometastases and isolated tumor cells in lymph nodes: an in vivo study. In Vivo 2008;22(6):707-12. [PUBMED: 19180995].
38. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer 2010;127(12):2893-917.
39. Fisher DJ, Copas AJ, Tierney JF, Parmar MKB. A critical review of methods for the assessment of patient-level interactions in individual participant data meta-analysis of randomized trials, and guidance for practitioners. Journal of Clinical Epidemiology 2011;64:949-67.
40. Forman D, Burley VJ. Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Practice and Research. Clinical Gastroenterology 2006;20(4):633-49.
41. Gallo A, Cha C. Updates on esophageal and gastric cancers. World Journal of Gastroenterology 2006;12(20):3237-42.
42. Hagen JA, DeMeester SR, Peters JH, Chandrasoma P, DeMeester TR. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Annals of Surgery 2001;234(4):520-30.
43. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
44. Kelsen DP. Adjuvant and neoadjuvant therapy for gastric cancer. Seminars in Oncology 1996;23(3):379-89.
45. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al.Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New England Journal of Medicine 2001;345(10):725-30.
46. Malthaner RA, Wong RK, Rumble RB, Zuraw L. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Medicine 2004;2:35.
47. Marsman WA, Tytgat GN, Ten Kate FJ, van Lanschot JJ. Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction. Journal of Surgical Oncology 2005;92(3):160-8.
48. McCulloch P, Ward J, Tekkis PP. Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ (Clinical research ed.) 2003;327(7425):1192-7. [PUBMED: 14630753].
49. Munene G, Francis W, Garland SN, Pelletier G, Mack LA, Bathe OF. The quality of life trajectory of resected gastric cancer. Journal of Surgical Oncology 2012;105(4):337-41. [PUBMED: 22095440].
50. Ott K, Sendler A, Becker K, Dittler HJ, Helmberger H, Busch R, et al.Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 2003;6(3):159-67.
51. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, et al.Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303(17):1729-37.
52. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
53. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006;295:676-80.
54. Pignon JP, Hill C. Meta-analyses of randomised clinical trials in oncology. Lancet 2001;2:475-82.
55. R Foundation for Statistical Computing. R. 2.11.0. Vienna: R Foundation for Statistical Computing, 2010.
56. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
57. Riley RD, Simmonds MC, Look MP. Evidence synthesis combining individual patient data and aggregate data: a systematic review identified current practice and possible methods. Journal of Clinical Epidemiology 2007;60:431-9.
58. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 2010;340:c221.
59. SAS Institute. SAS. 9.2 and 9.3. Cary, North Carolina: SAS Institute, 2008 and 2011.
60. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Controlled Clinical Trials 1996;17:343-6.
61. Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, et al.Molecular classification of gastric cancer: a new paradigm. Clinical Cancer Research 2011;17(9):2693-701. [PUBMED: 21430069].
62. Siewert JR, Holscher AH, Becker K, Gossner W. Cardia cancer: attempt at a therapeutically relevant classification [Kardiacarcinom: Versuch einer therapeutisch relevanten Klassifikation]. Chirurg 1987;58(1):25-32.
63. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Annals of Surgery 1998;228(4):449-61.
64. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al.Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncology 2011;7:681-92.
65. Slanger TE, Schwarzbach M, Hofheinz R, Kienle P, Jensen K, Kieser M, et al.Perioperative chemotherapy versus primary surgery for locoregionally advanced resectable adenocarcinoma of the stomach, gastroesophageal junction and lower esophagus. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD008107].
66. Sobin LH, Wittekind C, Sobin LH, Wittekind C. In: Sobin LH, Wittekind C editor(s). TNM Classification of Malignant Tumours (UICC). New York: Wiley-Liss, 2002.
67. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al.Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. Journal of Clinical Oncology 2009;27(6):851-6.
68. Stewart LA, Clarke MJ. Practical methodology of meta-analyses (overviews) using updated individual patient data. Statistics in Medicine 1995;14:2057-79.
69. Thirion PG, Michiels S, Le Maître A, Tierney J, on behalf of the MetaAnalysis of Chemotherapy in Esophagus Cancer Collaborative Group. Individual patient data-based meta-analysis assessing pre-operative chemotherapy in resectable oesophageal carcinoma. Journal of Clinical Oncology 2007;25(18S):4512.
70. Thirion P, Maillard E, Pignon J. Individual patient data-based meta-analysis assessing the effect of preoperative chemo-radiotherapy in resectable oesophageal carcinoma. International Journal of Radiation Oncology, Biology, Physics. Elsevier Science Inc., 2008; Vol. 72, issue 1:S71-2.
71. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
72. Verger E, Salamero M, Conill C. Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group Scoring Scale and vice-versa. European Journal of Cancer 1992;28A(8-9):1328-30.
73. Vial M, Grande L, Pera M. Epidemiology of adenocarcinoma of the esophagus, gastric cardia, and upper gastric third. Recent Results in Cancer Research 2010;182:1-17.
74. Vogt K, Fenlon D, Rhodes S, Malthaner R. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD001556.pub2].
75. Williamson PR, Smith CT, Hutton JL, Marson AG. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine 2002;21(22):3337-51.
76. Wu AW, Xu GW, Wang HY, Ji JF, Tang JL. WITHDRAWN: Neoadjuvant chemotherapy versus none for resectable gastric cancer. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005047.pub3].